GlassScriptPhysician profile
Abdul Qadir
NPI 1992718100
$2,764.15
in general payments reported to CMS, 2019-2025
26 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $292 · 2020: $131 · 2021: $93.75 · 2022: $73.58 · 2023: $520 · 2024: $607 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,077 · Education: $96.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,077.46 |
| Education | $96.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $597.66 | 2019-2025 | Briviact, Nayzilam, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $420.62 | 2020-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Abbvie INC. | $232.56 | 2024-2025 | |
| Neurelis, INC. | $205.17 | 2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $180.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $141.14 | 2023-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $129.32 | 2023-2024 | Aptiom |
| Pfizer INC. | $106.97 | 2023-2025 | |
| W. L. Gore & Associates, INC. | $92.00 | 2025 | Gore Synecor Biomaterial |
| Argenx US, INC. | $72.53 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $70.03 | 2020-2021 | |
| Lilly USA, LLC | $66.94 | 2023-2024 | Emgality, Amyvid |
| Lundbeck LLC | $61.03 | 2024-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $60.99 | 2022 | |
| Immedica Pharma US, INC. | $48.73 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.18 | 2020 | |
| Sk Life Science, INC. | $44.60 | 2024-2025 | |
| Eisai INC. | $34.46 | 2024-2025 | |
| Forte Bio-Pharma LLC | $27.89 | 2025 | Tanlor |
| Scilex Pharmaceuticals INC. | $24.92 | 2025 | |
| Allergan, INC. | $21.04 | 2020 | |
| Grifols USA, LLC | $20.79 | 2025 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $18.78 | 2024 | Crexont |
| Neurocrine Biosciences, INC. | $14.58 | 2024 | Ingrezza |
| Medtronic USA, INC. | $11.93 | 2019 | |
| Aucta Pharmaceuticals, INC. | $11.66 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Qadir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.